• Je něco špatně v tomto záznamu ?

Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis

B. Srpova, T. Uher, T. Hrnciarova, C. Barro, M. Andelova, Z. Michalak, M. Vaneckova, J. Krasensky, L. Noskova, EK. Havrdova, J. Kuhle, D. Horakova

. 2021 ; 27 (1) : 52-60. [pub] 20200121

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026295

BACKGROUND: Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury. There is a lack of studies investigating the dynamics of relationships between sNfL levels and radiological disease activity over long-term follow-up in multiple sclerosis (MS). OBJECTIVES: To investigate the relationship among repeated measures of sNfL, lesion burden accumulation, brain volume loss and clinical measures. METHODS: We investigated 172 patients in the early stages of MS (McDonald 2017 criteria). Clinical exams were performed every 3 months and brain magnetic resonance imaging (MRI) scans were collected annually over 48 months. sNfL levels were measured in serum by Simoa assay at the time of treatment initiation and then annually over 36 months. RESULTS: In repeated-measures analysis, considering all time points, we found a strong relationship between percentage changes of sNfL and lesion burden accumulation assessed by T1 lesion volume (p < 0.001) and T2 lesion number (p < 0.001). There was no relationship between percentage changes of sNfL and brain volume loss over 36 months (p > 0.1). Early sNfL levels were associated with delayed brain volume loss after 48 months (p < 0.001). Patients with No Evidence of Disease Activity (NEDA-3) status showed lower sNfL levels compared with active MS patients. CONCLUSIONS: sNfL is associated with ongoing neuroinflammation and predictive of future neurodegeneration in early MS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026295
003      
CZ-PrNML
005      
20240903113256.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458519901272 $2 doi
035    __
$a (PubMed)31961243
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Srpová, Barbora $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0321726
245    10
$a Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis / $c B. Srpova, T. Uher, T. Hrnciarova, C. Barro, M. Andelova, Z. Michalak, M. Vaneckova, J. Krasensky, L. Noskova, EK. Havrdova, J. Kuhle, D. Horakova
520    9_
$a BACKGROUND: Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury. There is a lack of studies investigating the dynamics of relationships between sNfL levels and radiological disease activity over long-term follow-up in multiple sclerosis (MS). OBJECTIVES: To investigate the relationship among repeated measures of sNfL, lesion burden accumulation, brain volume loss and clinical measures. METHODS: We investigated 172 patients in the early stages of MS (McDonald 2017 criteria). Clinical exams were performed every 3 months and brain magnetic resonance imaging (MRI) scans were collected annually over 48 months. sNfL levels were measured in serum by Simoa assay at the time of treatment initiation and then annually over 36 months. RESULTS: In repeated-measures analysis, considering all time points, we found a strong relationship between percentage changes of sNfL and lesion burden accumulation assessed by T1 lesion volume (p < 0.001) and T2 lesion number (p < 0.001). There was no relationship between percentage changes of sNfL and brain volume loss over 36 months (p > 0.1). Early sNfL levels were associated with delayed brain volume loss after 48 months (p < 0.001). Patients with No Evidence of Disease Activity (NEDA-3) status showed lower sNfL levels compared with active MS patients. CONCLUSIONS: sNfL is associated with ongoing neuroinflammation and predictive of future neurodegeneration in early MS.
650    _2
$a biologické markery $7 D015415
650    _2
$a mozek $x diagnostické zobrazování $7 D001921
650    _2
$a lidé $7 D006801
650    _2
$a zánět $x diagnostické zobrazování $7 D007249
650    _2
$a intermediární filamenta $7 D007382
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    12
$a roztroušená skleróza $x diagnostické zobrazování $7 D009103
650    _2
$a neurofilamentové proteiny $7 D016900
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Uher, Tomas $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hrnciarova, Tereza $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Barro, Christian $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Andelova, Michaela $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Michalak, Zuzanna $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Vaneckova, Manuela $u Department of Radiology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Krasensky, Jan $u Department of Radiology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Noskova, Libuse $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kuhle, Jens $u Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00006389 $t Multiple sclerosis $x 1477-0970 $g Roč. 27, č. 1 (2021), s. 52-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31961243 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240903113253 $b ABA008
999    __
$a ok $b bmc $g 1715115 $s 1146802
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 1 $d 52-60 $e 20200121 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace